alirocumab

AssetAlso called Praluent, Praluent (Alirocumab), Alirocumab (Solution), REGN727

Inhibits PCSK9, increasing LDL receptor recycling and lowering circulating LDL cholesterol.

Stage
Approved
Modality
Antibody
Target
PCSK9
18
Indications
66
Trials
2
Developers

Approved by the FDA on Jul 24, 2015 (BLA125559). 2 approvals stand. FDA

Indications

18
  • Hypercholesterolemia

    Approved, EMA

  • Heterozygous familial hypercholesterolemia

    Approved, FDA

  • Atherosclerotic cardiovascular disease

    Approved, EMA

15 more

In the full profile

  • Target and mechanism1
  • Owner and partners2
  • Trials66
  • Evidence for its targets2
  • Competitors12
  • Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets